Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?

被引：2
|
作者：
Chen, Yang [1 ,2 ,3 ,4 ]
Guo, Lu-Ying [1 ,2 ,3 ,4 ]
Zhao, Ling-Fei [1 ,2 ,3 ,4 ]
Ma, Yan-Hong [1 ,2 ,3 ,4 ]
Zhu, Xue-Ling [5 ,6 ,7 ]
Xu, Ying [1 ,2 ,3 ,4 ]
Chen, Jiang-Hua [1 ,2 ,3 ,4 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Kidney Dis Ctr, Sch Med, Hangzhou, Zhejiang, Peoples R China
[2] Adm Tradit Chinese Med, Grade Lab Natl State 3, Hangzhou, Zhejiang, Peoples R China
[3] Key Lab Kidney Dis Prevent & Control Technol, Hangzhou, Zhejiang, Peoples R China
[4] Zhejiang Univ, Inst Nephrol, Natl Key Clin Dept Kidney Dis, Hangzhou, Zhejiang, Peoples R China
[5] State Key Lab Diag & Treatment Infect Dis, Hangzhou, Zhejiang, Peoples R China
[6] Zhejiang Univ, Affiliated Hosp 1, Natl Clin Res Ctr Infect Dis, Sch Med, Hangzhou, Zhejiang, Peoples R China
[7] Zhejiang Univ, Affiliated Hosp 1, Collaborat Innovat Ctr Diag & Treatment Infect Di, Sch Med, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF GERIATRIC CARDIOLOGY | 2020年 / 17卷 / 12期
关键词：
Cardiovascular disease; Chronic kidney disease; Kidney function; Sacubitril/valsartan; ANGIOTENSIN-NEPRILYSIN INHIBITION; HEART-FAILURE; CARDIOVASCULAR-DISEASE; ASSOCIATION; IRBESARTAN; LCZ696; EPIDEMIOLOGY; MANAGEMENT; MECHANISMS; ENALAPRIL;
D O I：
10.11909/j.issn.1671-5411.2020.12.002
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Chronic kidney disease (CKD) often coexists with or is a complication of cardiovascular disease. Previous studies have shown that CKD increases the risk of cardiovascular death and all-cause death and was considered to be a risk equivalent of coronary heart disease.[1,2] Adjusted for con-founders, decreased glomerular filtration rate (GFR) and increased albuminuria are both independent risk factors for cardiovascular events.[3,4] The risk for cardiovascular death linearly increases with the decline of GFR in a certain range (< 70 mL/min per 1.73 m2) and the increase of albuminuria without a threshold effect. © 2020 JGC All rights reserved; www.jgc301.com
引用
收藏
页码：782 / 786
页数：5
相关论文
共 50 条
  • [1] Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?
    Yang CHEN
    Lu-Ying GUO
    Ling-Fei ZHAO
    Yan-Hong MA
    Xue-Ling ZHU
    Ying XU
    Jiang-Hua CHEN
    Journal of Geriatric Cardiology, 2020, 17 (12) : 782 - 786
  • [2] Can sacubitril/valsartan become the promising drug to delay the progression of chronic kidney disease?
    Yang CHEN
    LuYing GUO
    LingFei ZHAO
    YanHong MA
    XueLing ZHU
    Ying XU
    JiangHua CHEN
    Journal of Geriatric Cardiology, 2020, 17 (12) : 782 - 786
  • [3] Sacubitril/valsartan in patients with chronic kidney disease, a promising path
    Toro, D. Prieto
    Gaitan Roman, D. Daniel
    Martinez Esteban, M. D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 48 - 48
  • [4] Drug therapies to delay the progression of chronic kidney disease
    Ward, Frank
    Holian, John
    Murray, Patrick T.
    CLINICAL MEDICINE, 2015, 15 (06) : 550 - 557
  • [5] Sacubitril/valsartan in chronic kidney disease, the nephrologist point of view
    Quiroga, Borja
    de Santos, Antonio
    Sapiencia, David
    Saharaui, Yamila
    Alvarez-Chiva, Vicente
    NEFROLOGIA, 2019, 39 (06): : 646 - 652
  • [6] A Retrospective Analysis of Sacubitril/Valsartan in Heart Failure and Chronic Kidney Disease
    McFarland, Kayla L.
    Sheridan, Erica A.
    JOURNAL OF PHARMACY TECHNOLOGY, 2023, 39 (03) : 117 - 122
  • [7] USE OF SACUBITRIL/VALSARTAN IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A NEW APPROACH
    Del Pozo Alvarez, Rafael
    Vazquez, Teresa
    Martinez Esteban, Dolores
    Gaitan Roman, Daniel
    Moreno Ortiz, Alicia
    Hernandez, Domingo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36
  • [8] CLINICAL EFFECTS OF ARNI (SACUBITRIL/ VALSARTAN) IN PATIENTS WITH CHRONIC KIDNEY DISEASE WITH HYPERTENSION
    Kobayashi, Norihiro
    Nakatani, Yoshihisa
    Shimizu, Kazuyuki
    Nakano, Yukihito
    Sakaguchi, Mika
    Arima, Shuji
    JOURNAL OF HYPERTENSION, 2023, 41 : E391 - E392
  • [9] Sacubitril/valsartan in chronic kidney disease: From pharmacological mechanism to clinical application
    Kuang, Huang
    Huang, Xin
    Zhou, Zhifeng
    Cheng, Xuexin
    Xu, Gaosi
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2021, 907
  • [10] EFFECTS OF ALLOCATION TO SACUBITRIL/VALSARTAN IN PATIENTS WITH NON-DIALYSIS CHRONIC KIDNEY DISEASE
    Tong, J.
    Ren, H.
    Ma, X. Y.
    Zhang, B. Y.
    Lin, L.
    Liu, N.
    Li, X.
    Xie, J. Y.
    Chen, N.
    NEPHROLOGY, 2021, 26 : 34 - 34
12345